No Data
No Data
Morgan Stanley Identifies 39 Stocks Likely to Face Tax Loss Selling Pressure
Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA) and Repligen (RGEN)
Repligen Analyst Ratings
RBC Capital Maintains Repligen(RGEN.US) With Buy Rating, Maintains Target Price $205
Repligen (NASDAQ:RGEN) Shareholder Returns Have Been Favorable, Earning 93% in 5 Years
Craig-Hallum Maintains Repligen(RGEN.US) With Buy Rating
Craig-Hallum analyst Matt Hewitt maintains $Repligen(RGEN.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 42.4% and a total average return of -4.2% over the past